E
RVMD icon

Ergoteles’s Revolution Medicines RVMD Stock Holding History

Ergoteles’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-9,100
Closed -$217K – 1693
2022
Q4 		$217K Buy
+9,100
New +$193K 0.01% 1041
2022
Q3 		– Sell
-16,600
Closed -$324K – 1925
2022
Q2 		$324K Buy
16,600
+500
+3% +$9.73K 0.01% 1071
2022
Q1 		$411K Sell
16,100
-195
-1% -$4.24K 0.02% 738
2021
Q4 		$410K Buy
+16,295
New +$459K 0.02% 721

Other funds holding RVMD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ergoteles's RVMD Position: Q1 2023 in Review

Ergoteles sold out of Revolution Medicines (RVMD) in Q1 2023, closing a stake of 9,100 shares — an estimated $217K sold.

Ergoteles first reported a position in RVMD in Q4 2021 and held it in 4 quarters. The position peaked at $411K in Q1 2022. 152 funds tracked by Wall St. Rank hold RVMD as of Q1 2023.

  • Ergoteles reported no remaining Revolution Medicines position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 9,100 Revolution Medicines shares in Q1 2023, an estimated $217K.
  • Ergoteles first reported a position in Revolution Medicines in Q4 2021 and held it in 4 quarters.
  • Ergoteles's Revolution Medicines position peaked at $411K in Q1 2022.
  • 152 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.